Yuji Komorita1,2, Masanori Iwase3,4, Hiroki Fujii5, Toshiaki Ohkuma1,6, Hitoshi Ide1,7, Tamaki Jodai-Kitamura1, Akiko Sumi1, Masahito Yoshinari1, Udai Nakamura1, Dongchon Kang2, Takanari Kitazono1. 1. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan. 2. Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 3. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan. iwase@intmed2.med.kyushu-u.ac.jp. 4. Diabetes Centre, Hakujyuji Hospital, Fukuoka, Japan. iwase@intmed2.med.kyushu-u.ac.jp. 5. Centre for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 6. The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia. 7. Division of General Internal Medicine, School of Oral Health Science, Kyushu Dental University, Kitakyushu, Japan.
Abstract
AIMS/HYPOTHESIS: Serum adiponectin has been reported to impact upon fracture risk in the general population. Although type 2 diabetes is associated with increased fracture risk, it is unclear whether serum adiponectin predicts fractures in individuals with type 2 diabetes. The aim of the study was to prospectively investigate the relationship between serum adiponectin and fracture risk in individuals with type 2 diabetes. METHODS: In this study, data was obtained from The Fukuoka Diabetes Registry, a multicentre prospective study designed to investigate the influence of modern treatments on the prognoses of patients with diabetes mellitus. We followed 4869 participants with type 2 diabetes (mean age, 65 years), including 1951 postmenopausal women (defined as self-reported amenorrhea for >1 year) and 2754 men, for a median of 5.3 years. The primary outcomes were fractures at any site and major osteoporotic fractures (MOFs). RESULTS: During the follow-up period, fractures at any site occurred in 682 participants, while MOFs occurred in 277 participants. Age-adjusted HRs (95% CIs) of any fracture and MOFs for 1 SD increment in log e -transformed serum adiponectin were 1.27 (1.15, 1.40) and 1.35 (1.17, 1.55) in postmenopausal women and 1.22 (1.08, 1.38) and 1.40 (1.15, 1.71) in men, respectively. HRs (95% CIs) of MOFs for hyperadiponectinaemia (≥ 20 μg/ml) were 1.72 (1.19, 2.50) in postmenopausal women and 2.19 (1.23, 3.90) in men. The per cent attributable risk of hyperadiponectinaemia for MOFs was as high as being age ≥70 years or female sex. CONCLUSIONS/ INTERPRETATION: Higher serum adiponectin levels were significantly associated with an increased risk of fractures at any site and with an increased risk of MOFs in individuals with type 2 diabetes, including postmenopausal women.
AIMS/HYPOTHESIS: Serum adiponectin has been reported to impact upon fracture risk in the general population. Although type 2 diabetes is associated with increased fracture risk, it is unclear whether serum adiponectin predicts fractures in individuals with type 2 diabetes. The aim of the study was to prospectively investigate the relationship between serum adiponectin and fracture risk in individuals with type 2 diabetes. METHODS: In this study, data was obtained from The Fukuoka Diabetes Registry, a multicentre prospective study designed to investigate the influence of modern treatments on the prognoses of patients with diabetes mellitus. We followed 4869 participants with type 2 diabetes (mean age, 65 years), including 1951 postmenopausal women (defined as self-reported amenorrhea for >1 year) and 2754 men, for a median of 5.3 years. The primary outcomes were fractures at any site and major osteoporotic fractures (MOFs). RESULTS: During the follow-up period, fractures at any site occurred in 682 participants, while MOFs occurred in 277 participants. Age-adjusted HRs (95% CIs) of any fracture and MOFs for 1 SD increment in log e -transformed serum adiponectin were 1.27 (1.15, 1.40) and 1.35 (1.17, 1.55) in postmenopausal women and 1.22 (1.08, 1.38) and 1.40 (1.15, 1.71) in men, respectively. HRs (95% CIs) of MOFs for hyperadiponectinaemia (≥ 20 μg/ml) were 1.72 (1.19, 2.50) in postmenopausal women and 2.19 (1.23, 3.90) in men. The per cent attributable risk of hyperadiponectinaemia for MOFs was as high as being age ≥70 years or female sex. CONCLUSIONS/ INTERPRETATION: Higher serum adiponectin levels were significantly associated with an increased risk of fractures at any site and with an increased risk of MOFs in individuals with type 2 diabetes, including postmenopausal women.
Entities:
Keywords:
Adiponectin; Cohort study; Fracture; Type 2 diabetes
Authors: C Huang; Y Tomata; M Kakizaki; Y Sugawara; A Hozawa; H Momma; I Tsuji; R Nagatomi Journal: Nutr Metab Cardiovasc Dis Date: 2015-03-27 Impact factor: 4.222
Authors: Heidi S Berner; Staale P Lyngstadaas; Axel Spahr; Marta Monjo; Liv Thommesen; Christian A Drevon; Unni Syversen; Janne E Reseland Journal: Bone Date: 2004-10 Impact factor: 4.398
Authors: Helena Johansson; John A Kanis; Anders Odén; Eugene McCloskey; Roland D Chapurlat; Claus Christiansen; Steve R Cummings; Adolfo Diez-Perez; John A Eisman; Saeko Fujiwara; Claus-C Glüer; David Goltzman; Didier Hans; Kay-Tee Khaw; Marc-Antoine Krieg; Heikki Kröger; Andrea Z LaCroix; Edith Lau; William D Leslie; Dan Mellström; L Joseph Melton; Terence W O'Neill; Julie A Pasco; Jerilynn C Prior; David M Reid; Fernando Rivadeneira; Tjerd van Staa; Noriko Yoshimura; M Carola Zillikens Journal: J Bone Miner Res Date: 2014-01 Impact factor: 6.741
Authors: Juliet E Compston; Julie Flahive; David W Hosmer; Nelson B Watts; Ethel S Siris; Stuart Silverman; Kenneth G Saag; Christian Roux; Maurizio Rossini; Johannes Pfeilschifter; Jeri W Nieves; J Coen Netelenbos; Lyn March; Andrea Z LaCroix; Frederick H Hooven; Susan L Greenspan; Stephen H Gehlbach; Adolfo Díez-Pérez; Cyrus Cooper; Roland D Chapurlat; Steven Boonen; Frederick A Anderson; Silvano Adami; Jonathan D Adachi Journal: J Bone Miner Res Date: 2014-02 Impact factor: 6.741
Authors: Julie M Paik; Harold N Rosen; Jeffrey N Katz; Bernard A Rosner; Eric B Rimm; Catherine M Gordon; Gary C Curhan Journal: Obesity (Silver Spring) Date: 2019-07-18 Impact factor: 5.002
Authors: Daniel González-Hedström; Ángel Luís García-Villalón; Sara Amor; María de la Fuente-Fernández; Paula Almodóvar; Marin Prodanov; Teresa Priego; Ana Isabel Martín; Antonio Manuel Inarejos-García; Miriam Granado Journal: Sci Rep Date: 2021-04-14 Impact factor: 4.379